|
Characteristics
|
Number of cases (%)
|
|---|
|
Age
|
|
Median, years (range)
|
54 (33–77)
|
|
< 60
|
29 (64.4)
|
|
≥ 60
|
16 (35.6)
|
|
Sex
|
|
Male
|
32 (71)
|
|
Female
|
13 (29)
|
|
ECOG performance score
|
|
0–1
|
43 (96)
|
|
2
|
2 (4)
|
|
Ann Arbor stage at diagnosis
|
|
III
|
11 (24)
|
|
IV
|
34 (76)
|
|
LDH
|
|
Within normal range
|
35 (78)
|
|
Elevated
|
7 (16)
|
|
Unchecked
|
3 (7)
|
|
B symptomsa
|
|
Absent
|
38 (84)
|
|
Present
|
7 (16)
|
|
BM involvement
|
|
Absent
|
34 (76)
|
|
Present
|
11 (24)
|
|
Histology
|
|
Nodal MZL
|
15 (33)
|
|
MZL of MALT-type
|
30 (67)
|
|
Lung
|
8 (18)
|
|
Ocular and adnexa
|
6 (13)
|
|
Stomach
|
4 (9)
|
|
Bone
|
2 (4)
|
|
Nasopharynx
|
2 (4)
|
|
Multiple MALT sites
|
3 (7)
|
|
Othersb
|
5 (11)
|
|
IPI score
|
|
1
|
13 (29)
|
|
2
|
21 (47)
|
|
3
|
9 (20)
|
|
4
|
2 (4)
|
|
Response to prior R–CVP
|
|
CR
|
20 (44)
|
|
PR
|
22 (49)
|
|
SD
|
3 (7)
|
|
No. first line R–CVP (6 cycles)
|
10 (22)
|
|
Treatment cycles (8 cycles)
|
35 (78)
|
- Values are expressed as n (%) unless indicated otherwise
- BM bone marrow, CR complete response, ECOG Eastern Clinical Oncology Group, IPI International Prognostic Index, LDH lactate dehydrogenase, MALT mucosa-associated lymphoid tissue, MZL marginal zone B-cell lymphoma, PR partial response, R–CVP rituximab cyclophosphamide vincristine prednisolone, SD stable disease
- aFever, night sweats, and/or weight loss
- bOne case each in the kidney, liver, nasal cavity, subcutaneous tissue, and small intestine
